Alterity Therapeutics Ltd
ATHE3.530USD
+0.330+10.31%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
53.70MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Alterity Therapeutics Ltd Unternehmen
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Alterity Therapeutics Ltd Informationen
BörsenkürzelATHE
Name des UnternehmensAlterity Therapeutics Ltd
IPO-datumMar 28, 2000
CEOStamler (David A)
Anzahl der mitarbeiter9
WertpapierartDepository Receipt
GeschäftsjahresendeMar 28
AddresseLevel 14, 350 Collins Street
StadtMELBOURNE
BörseNASDAQ OMX - NASDAQ BASIC
LandAustralia
Postleitzahl3000
Telefon61393494906
Websitehttps://alteritytherapeutics.com/
BörsenkürzelATHE
IPO-datumMar 28, 2000
CEOStamler (David A)
Führungskräfte von Alterity Therapeutics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Twin Lakes Capital
0.77%
Morgan Stanley & Co. LLC
0.38%
Homrich Berg
0.32%
Greenleaf Trust
0.18%
Citadel Advisors LLC
0.12%
Andere
98.23%
Aktionäre
Aktionäre
Anteil
Twin Lakes Capital
0.77%
Morgan Stanley & Co. LLC
0.38%
Homrich Berg
0.32%
Greenleaf Trust
0.18%
Citadel Advisors LLC
0.12%
Andere
98.23%
Aktionärstypen
Aktionäre
Anteil
Private Equity
0.77%
Research Firm
0.42%
Investment Advisor/Hedge Fund
0.36%
Bank and Trust
0.18%
Hedge Fund
0.12%
Andere
98.15%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
31
335.79K
1.62%
--
2025Q3
31
335.79K
1.62%
+112.77K
2025Q2
26
223.02K
2.05%
-19.87K
2025Q1
25
242.89K
2.06%
+14.64K
2024Q4
25
125.45K
2.26%
+11.61K
2024Q3
25
113.89K
1.99%
+34.70K
2024Q2
24
79.19K
2.01%
-15.98K
2024Q1
24
95.17K
1.68%
-51.08K
2023Q4
23
88.25K
2.56%
+29.17K
2023Q3
26
59.08K
3.01%
-573.00
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Twin Lakes Capital
139.26K
0.77%
+133.33K
+2250.35%
Sep 30, 2025
Morgan Stanley & Co. LLC
68.62K
0.38%
+10.38K
+17.83%
Sep 30, 2025
Homrich Berg
58.46K
0.32%
+58.46K
--
Sep 30, 2025
Greenleaf Trust
32.00K
0.18%
+15.00K
+88.24%
Sep 30, 2025
Citadel Advisors LLC
22.14K
0.12%
+22.14K
--
Sep 30, 2025
BNP Paribas Securities Corp. North America
7.31K
0.04%
-881.00
-10.76%
Sep 30, 2025
Acadian Asset Management LLC
4.80K
0.03%
+4.80K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
1.16K
0.01%
--
--
Nov 30, 2025
Rhumbline Advisers Ltd. Partnership
886.00
0%
+756.00
+581.54%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
